Jasińska E, Habek M, Wynnet D, et al. Impact of Ofatumumab on Immune Responses Post-vaccination in RMS Patients: ALITHIOS Vaccination Sub-study Design. Oral presentation at: EAN 2021; June 19-22, 2021.
Furst D. Serum immunoglobulins and risk of infection: how low can you go? Seminars in Arthritis and Rheumatism. 2009;39(1):18-29.
Tallantyre E, Whittam D, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115–1122.
Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2020;383(6):546-557.